Send me real-time posts from this site at my email
Motley Fool

Why Dynavax Technologies Stock Is Soaring Today

What happened

Shares of Dynavax Technologies (NASDAQ: DVAX) are on the move after the company's vaccine adjuvant was featured in a positive clinical trial readout. Investors excited about the results have pushed the biotech stock 26.6% higher as of 12:02 p.m. EDT on Wednesday.

So what

Today, Dynavax's collaboration partner, Clover Biopharmaceuticals, reported positive results from the pivotal Spectra trial with Clover's COVID-19 vaccine candidate, SCB-2019. This is a protein-based vaccine that employs a booster, or adjuvant, from Dynavax.

Image source: Getty Images.

The Spectra trial enrolled over 30,000 adults in five countries spread across four continents. Clearly, delta and other variants of concern had already taken over when the trial enrolled volunteers. None of those who tested positive were infected with the original virus responsible for COVID-19.

Against the delta variant, SCB-2019 was 79% effective against COVID-19 of any severity. The stock would have risen much further, but overall efficacy was only 67% against COVID-19 infection of any variety.

Now what

Dynavax investors shouldn't be too disappointed with the relatively low overall efficacy rate. The more established vaccines from Moderna and Pfizer were tested before today's variants of concern had taken over.

The Spectra trial with SCB-2019 is sponsored by the Coalition for Epidemic Preparedness Innovations, or CEPI. This is one of the entities behind the Covax initiative to expand vaccine access worldwide.

There's a good chance that Covax will pick up what Dynavax and Clover are putting down. None of the volunteers randomized to receive SCB-2019 were hospitalized or died from any COVID-19 variant.

10 stocks we like better than Dynavax Technologies
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Dynavax Technologies wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 17, 2021

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue